BrainStorm receives key U.S. patent

|About: BrainStorm Cell Therapeut... (BCLI)|By:, SA News Editor

BrainStorm Cell Therapeutics (BCLI) has received a U.S. patent for its stem cell technology, which it is developing for neurodegenerative conditions.

The IP covers stem cells that are induced to secrete elevated levels of neurotrophic factors.

Separately, Brainstorm has signed an agreement with Massachusetts General Hospital to conduct a Phase II trial of BrainStorm's NurOwn therapy in Lou Gehrig's, pending FDA approval.

The other two sites are set to be University of Massachusetts Memorial Hospital and Mayo Clinic. (PR)